OncLive.com @OncLive · 03 Sep 2026
🗞️Just in: Topline data from the phase 3 CERVINO trial showed etentamig generated statistically significant improvements in PFS and ORR vs standard therapies in patients with triple-class exposed R/R myeloma #mmsm #oncology Dive into the efficacy and safety highlights: https://t.co/UahyJcvHgl
66Views
0Likes
0Reposts
0Replies
0Quotes
0Bookmarks
Is that a lot?
0.55×vs this author's median120 views is typical
0Percentile for this authorof 5 recent posts
0.02×vs 10K–100K median2 896 views is typical
0.13%Reachviews ÷ followers
0.00%Engagement rateof viewers reacted